RedHill Biopharma reported $5.51M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Cara Therapeutics USD 5.94M 983K Sep/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.29M 1.51M Dec/2025
Cronos Group USD 51.59M 70.5M Dec/2025
RedHill Biopharma USD 5.51M 1.08M Jun/2024